Non-Small-Cell Lung Clinical Trials

2 recruiting

Non-Small-Cell Lung Trials at a Glance

21 actively recruiting trials for non-small-cell lung are listed on ClinicalTrialsFinder across 6 cities in 36 countries. The largest study group is Phase 2 with 9 trials, with the heaviest enrollment activity in Houston, Los Angeles, and Dijon. Lead sponsors running non-small-cell lung studies include AstraZeneca, Alentis Therapeutics AG, and Pfizer.

Browse non-small-cell lung trials by phase

Treatments under study

About Non-Small-Cell Lung Clinical Trials

Looking for clinical trials for Non-Small-Cell Lung? There are currently 2 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Non-Small-Cell Lung trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Non-Small-Cell Lung clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 120 of 21 trials

Recruiting
Phase 1

Phase 1 Study of PF-08046033 in Advanced Solid Tumors

Esophageal CancerCutaneous MelanomaNon-Small-Cell Lung
Pfizer250 enrolled6 locationsNCT07519655
Recruiting

NIS to Examine the Effectiveness of TDC in Patients With Metastatic Non-squamous NSCLC and High-risk Genetic Alterations

Non-squamous Metastatic Non-Small-Cell Lung Carcinoma
AstraZeneca600 enrolled23 locationsNCT06494540
Recruiting
Not Applicable

Analysis of the Effectiveness and Safety of Lorlatinib in Untreated ALK-Positive NSCLC Patients in a French Real-World Context

ALK+ Non-Small-Cell Lung Carcinoma
Pfizer90 enrolled4 locationsNCT06487078
Recruiting
Phase 2

Study Investigating ASP3082 in Patients With Metastatic/Locally Advanced Non-small-cell Lung Cancer (NSCLC) and Pancreatic Ductal Adenocarcinoma (PDAC), With Biomarker Analysis to Characterize Response/Resistance

Metastatic/Locally Advanced Non-Small-Cell Lung CancerMetastatic/Locally Pancreatic Ductal Adenocarcinoma
Gustave Roussy, Cancer Campus, Grand Paris60 enrolled6 locationsNCT07483983
Recruiting
Phase 1Phase 2

A Study to Investigate ALE.P03 as Monotherapy in Adult Patients With Selected Advanced or Metastatic CLDN1+ Solid Tumors

Squamous Non-small-cell Lung CancerCervical Squamous Cell Carcinoma
Alentis Therapeutics AG180 enrolled28 locationsNCT07169734
Recruiting
Phase 1

A First-in-human Study of BGB-53038, a Pan-KRAS Inhibitor, Alone or in Combinations in Participants With Advanced or Metastatic Solid Tumors With KRAS Mutations or Amplification

Advanced Gastric CancerMetastatic Solid TumorsAdvanced Non-squamous Non-small-cell Lung Cancer+4 more
BeiGene514 enrolled17 locationsNCT06585488
Recruiting

A Study of Biological, Genetic, and Constitutional Factors and Non-invasive Monitoring to Assess Personal Cancer Risks

Breast CancerOvarian CancerColo-rectal Cancer+2 more
Fondazione del Piemonte per l'Oncologia850 enrolled1 locationNCT07469709
Recruiting
Phase 2

An Adjuvant Study to Evaluate SMS001 (Paclitaxel) in Non-Small Cell Lung Cancer

Carcinoma, Non-Small-Cell Lung Cancer (NSCLC)
ToLymph Inc.42 enrolled2 locationsNCT06693336
Recruiting
Phase 1Phase 2

A Study to Investigate ALE.P02 as Monotherapy in Adult Patients With Selected CLDN1+ Solid Tumors

Esophageal Squamous Cell CarcinomaHead and Neck Squamous Cell CarcinomaSquamous Non-small-cell Lung Cancer+1 more
Alentis Therapeutics AG170 enrolled38 locationsNCT06747585
Recruiting
Phase 2

IBI363 (PD-1/IL-2α-bias) in Combination With Chemotherapy as Neoadjuvant Therapy in Initially Unresectable Stage III Non-Small Cell Lung Cancer

Carcinoma, Non-Small-Cell Lung Cancer (NSCLC)Unresectable Stage III Non-small Cell Lung Cancer
Shanghai Pulmonary Hospital, Shanghai, China43 enrolled1 locationNCT07408635
Recruiting
Phase 2

Randomized Trial Comparing Standard of Care Versus Immune- Based Combination in Relapsed Stage III Non-small-cell Lung Cancer (NSCLC) Pretreated With Chemoradiotherapy and Durvalumab

Non-small-cell Lung Cancer Patients
Fondazione Ricerca Traslazionale176 enrolled1 locationNCT05568212
Recruiting
Phase 1Phase 2

A Study of AZD2936 Anti-TIGIT/Anti-PD-1 Bispecific Antibody in Participants With Advanced or Metastatic NSCLC

Non-Small-Cell Lung Carcinoma
AstraZeneca210 enrolled48 locationsNCT04995523
Recruiting
Phase 1Phase 2

A Phase I/II Study of VLS-1488 in Subjects With Advanced Cancer

Advanced Solid TumorHigh Grade Serous Adenocarcinoma of OvarySquamous Non-small-cell Lung Cancer
Volastra Therapeutics, Inc.200 enrolled14 locationsNCT05902988
Recruiting
Phase 2

Efficacy & Safety of Olvimulogene Nanivacirepvec & Platinum-doublet + Physician's Choice of Immune Checkpoint Inhibitor Compared to Docetaxel in NSCL Cancer

Advanced Non-squamous Non-small-cell Lung CancerAdvanced Squamous Non-Small Cell Lung Carcinoma
Genelux Corporation142 enrolled16 locationsNCT06463665
Recruiting

Prospective Cohort Study Evaluating 18FDG PET-CT for the Early Prediction of the Efficacy of Immunotherapy Associated or Not With Chemotherapy in Patients With Locally Advanced or Metastatic Non-Small Cell Broncho-Pulmonary Carcinoma

Carcinoma, Non-Small-Cell Lung (NSCLC)
Centre Antoine Lacassagne200 enrolled1 locationNCT06833229
Recruiting
Phase 3

JAB-21822 Combined With JAB-3312 Compared SOC in the First Line for Treatment of Advanced Non-small Cell Lung Cancer With KRAS p.G12C Mutation

Advanced Non-squamous Non-small-cell Lung Cancer
Allist Pharmaceuticals, Inc.392 enrolled37 locationsNCT06416410
Recruiting
Phase 1

Safety Study for a Gamma Delta T Cell Product Used With Low Dose Radiotherapy in Patients With Locally Advanced or Metastatic NSCLC or Solid Tumors With Bone Metastases

Carcinoma, Non-Small-Cell Lung CancerBone Metastases From Solid Tumors
Kiromic BioPharma Inc.48 enrolled5 locationsNCT06069570
Recruiting

A Post Approval Commitment Study on Tabrecta® (Capmatinib) in South Korea

Non-Small-Cell Lung Carcinoma
Novartis Pharmaceuticals250 enrolled12 locationsNCT05703516
Recruiting
Phase 3

Savolitinib Plus Osimertinib Versus Platinum-based Doublet Chemotherapy in Participants With Non-Small Cell Lung Cancer Who Have Progressed on Osimertinib Treatment

CarcinomaNon-Small-Cell Lung
AstraZeneca324 enrolled283 locationsNCT05261399
Recruiting
Not Applicable

Feasibility of Primer Shot Radiotherapy for Non-small Cell Lung Cancer - PRIMER

Patients With Non-small-cell Lung Cancer
The Netherlands Cancer Institute34 enrolled1 locationNCT06528743